Several therapeutic approaches have been explored for BAP1-deficient tumours, including chemotherapeutic drugs (e.g. gemcitabine), radiotherapy and small molecule inhibitors (e.g. EZH2 inhibitors) with limited success16–20. The gene discussed is EZH2; the disease is neoplasm.